MedTrace Logo

A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

NCT05388916 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2025-12-29

No results posted yet for this study

Summary

This was a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for up to 52 weeks.

Conditions

  • Moderate to Severe Chronic Plaque Psoriasis

Interventions

OTHER

Cosentyx

Prospective observational cohort study. There was treatment allocation.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-08
Primary Completion
2025-02-27
Completion
2025-02-27

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05388916 on ClinicalTrials.gov